BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37247463)

  • 1. Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway.
    Dabour MS; Abdelgawad IY; Grant MKO; El-Sawaf ES; Zordoky BN
    Biomed Pharmacother; 2023 Aug; 164():114907. PubMed ID: 37247463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
    Mancini SJ; Boyd D; Katwan OJ; Strembitska A; Almabrouk TA; Kennedy S; Palmer TM; Salt IP
    Sci Rep; 2018 Mar; 8(1):5276. PubMed ID: 29588466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
    Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
    Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
    Uthman L; Kuschma M; Römer G; Boomsma M; Kessler J; Hermanides J; Hollmann MW; Preckel B; Zuurbier CJ; Weber NC
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1083-1094. PubMed ID: 33048256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.
    Hawley SA; Ford RJ; Smith BK; Gowans GJ; Mancini SJ; Pitt RD; Day EA; Salt IP; Steinberg GR; Hardie DG
    Diabetes; 2016 Sep; 65(9):2784-94. PubMed ID: 27381369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice.
    Day EA; Ford RJ; Lu JH; Lu R; Lundenberg L; Desjardins EM; Green AE; Lally JSV; Schertzer JD; Steinberg GR
    Biochem J; 2020 Jun; 477(12):2347-2361. PubMed ID: 32510137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos.
    Huttunen R; Sainio A; Hjelt A; Haapanen-Saaristo AM; Määttä J; Rummukainen P; Paatero I; Järveläinen H
    Biomed Pharmacother; 2022 Dec; 156():113882. PubMed ID: 36265308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canagliflozin promotes osteoblastic MC3T3-E1 differentiation
    Song P; Chen T; Rui S; Duan X; Deng B; Armstrong DG; Ma Y; Deng W
    Front Endocrinol (Lausanne); 2022; 13():1081039. PubMed ID: 36589840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
    Shoda K; Tsuji S; Nakamura S; Egashira Y; Enomoto Y; Nakayama N; Shimazawa M; Iwama T; Hara H
    Cell Mol Neurobiol; 2023 Mar; 43(2):879-892. PubMed ID: 35435536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice.
    Rahadian A; Fukuda D; Salim HM; Yagi S; Kusunose K; Yamada H; Soeki T; Sata M
    J Atheroscler Thromb; 2020 Nov; 27(11):1141-1151. PubMed ID: 32101837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 Inhibitors May Restore Endothelial Barrier Interrupted by 25-Hydroxycholesterol.
    Pawlos A; Broncel M; Woźniak E; Markiewicz Ł; Piastowska-Ciesielska A; Gorzelak-Pabiś P
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway.
    Yang X; Liu Q; Li Y; Tang Q; Wu T; Chen L; Pu S; Zhao Y; Zhang G; Huang C; Zhang J; Zhang Z; Huang Y; Zou M; Shi X; Jiang W; Wang R; He J
    Adipocyte; 2020 Dec; 9(1):484-494. PubMed ID: 32835596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK.
    Angé M; De Poortere J; Ginion A; Battault S; Dechamps M; Muccioli GG; Roumain M; Morelle J; Druart S; Mathivet T; Bertrand L; Castanares-Zapatero D; Horman S; Beauloye C
    Sci Rep; 2021 Jul; 11(1):13700. PubMed ID: 34211080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin.
    Efentakis P; Kremastiotis G; Varela A; Nikolaou PE; Papanagnou ED; Davos CH; Tsoumani M; Agrogiannis G; Konstantinidou A; Kastritis E; Kanaki Z; Iliodromitis EK; Klinakis A; Dimopoulos MA; Trougakos IP; Andreadou I; Terpos E
    Blood; 2019 Feb; 133(7):710-723. PubMed ID: 30482794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
    Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
    Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization,
    Fathy Elhabal S; El-Nabarawi MA; Abdelaal N; Elrefai MFM; Ghaffar SA; Khalifa MM; Mohie PM; Waggas DS; Hamdan AME; Alshawwa SZ; Saied EM; Elzohairy NA; Elnawawy T; Gad RA; Elfar N; Mohammed H; Khasawneh MA
    Drug Deliv; 2023 Dec; 30(1):2241665. PubMed ID: 37537858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy.
    Bardaweel S; Issa A
    J Pharm Pharm Sci; 2022; 25():253-265. PubMed ID: 35977549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
    Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells.
    Li Q; Yue Y; Chen L; Xu C; Wang Y; Du L; Xue X; Liu Q; Wang Y; Fan F
    Front Pharmacol; 2018; 9():334. PubMed ID: 29867453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.